UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/737,252	12/15/2003	Toshiaki Maruyama	ALEX - PO2-077	6679
28120 FISH & NEA\	7590 05/30/2007 VE IP GROUP		EXAMINER	
ROPES & GRAY LLP			VANDERVEGT, FRANCOIS P	
ONE INTERN BOSTON, MA	IATIONAL PLACE N 02110-2624		ART UNIT	PAPER NUMBER
			1644	
			MAIL DATE	DELIVERY MODE
			05/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)				
	Office Action Summers	10/737,252	MARUYAMA ÉT AL.				
	Office Action Summary	Examiner	Art Unit				
		F. Pierre VanderVegt	1644				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with t	he correspondence address				
WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.11 SIX (6) MONTHS from the mailing date of this communication. It is specified above, the maximum statutory period or reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICAT 36(a). In no event, however, may a reply will apply and will expire SIX (6) MONTHS , cause the application to become ABAND	FION. be timely filed from the mailing date of this communication. DONED (35 U.S.C. § 133).				
Status		•					
1)⊠	Responsive to communication(s) filed on 15 Fe	ebruary 2007.					
2a)⊠	This action is FINAL . 2b) This action is non-final.						
3)							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5)□ 6)⊠ 7)⊠	Claim(s) 1-12 is/are pending in the application 4a) Of the above claim(s) 1-8 and 10 is/are with Claim(s) is/are allowed. Claim(s) 9 and 11 is/are rejected. Claim(s) 12 is/are objected to. Claim(s) are subject to restriction and/or	ndrawn from consideration.					
Applicat	ion Papers						
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine The specification is objected to be specification to the specification is objected to be specification.	epted or b) objected to by drawing(s) be held in abeyance. tion is required if the drawing(s)	See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).				
Priority (under 35 U.S.C. § 119		•				
a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea See the attached detailed Office action for a list	is have been received. Is have been received in Appl Irity documents have been rec u (PCT Rule 17.2(a)).	lication No ceived in this National Stage				
•	oee the attached detailed Office action for a list	of the certified copies not rec					
		•	•				
			•				
Attachmen		Λ Π Interniture 0	mon/ (PTO 413)				
2) Noti 3) Info	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date		mary (P10-413) Mail Date rmal Patent Application				

Application/Control Number: 10/737,252

Art Unit: 1644

DETAILED ACTION

This application is a continuation-in-part of U.S. Application Serial Number 10/251,085, which claims the benefit of the filing date of provisional application 60/323,455.

New claim 12 has been added.

Claims 1-12 are currently pending.

Election/Restrictions

1. Claims 1-8 and 10 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on July 27, 2006.

New claim 12 reads upon the elected invention and is included in the instant Office Action.

Accordingly, claims 9, 11 and 12 are the subject of examination in the present Office Action.

2. This application contains claims 1-8 and 10, drawn to an invention nonelected with traverse in the reply filed on July 27, 2006. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. Claims 9 and 11 stand rejected under 35 U.S.C. 102(b) as being anticipated by Moreno de Alboran et al (Immunotechnology [1995] 1(1):21-28; U on form PTO-892).

It was previously stated: "The claims are drafted in a product by process manner and drawn to a library of IgA antibodies wherein each antibody consists of at least a portion of an antibody [claim 9] and a single antibody with an identified binding specificity [claim 11]. The library is constructed using a recombinant amplification technique.

Moreno de Alboran teaches a combinatorial library of IgA antibodies on the surface of filamentous phage [claim 9]. Moreno de Alboran further teaches two antibodies from the library that have been selected for their reactivity with a specific antigen [claim 11] (Abstract in particular). The prior art teaching anticipates the claimed invention."

Application/Control Number: 10/737,252

Art Unit: 1644

Applicant's arguments filed February 15, 2007 have been fully considered but they are not persuasive.

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., entire human repertoire of IgA antibodies) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Applicant further argues that Moreno de Alboran is not anticipatory because it does not teach all elements of the claimed invention because the method of Moreno de Alboran is a two-primer method, while the instantly disclosed method is a one-primer method. Applicant is reminded first of all that the claims are not to the method but to a library. The claim is drafted in a product-by-process manner. However, a product remains the same irrespective of the manner in which it is made if the same product can be made by another process. In the instant case, both the claimed product and the teachings of Moreno de Alboran are drawn to a library of a library of IgA antibodies. There is no limitation in the claims that only one primer is used in the method of making the library. The claims are drafted in a manner that is sufficiently broad that would allow a library produced by the instantly claimed method to overlap with a library produced by the method taught by Moreno de Alboran. The fact that not all of the primers used by Moreno de Alboran will result in transcripts being made is not relevant because there is no limitation in the claims regarding the number of transcripts in the claimed library. Furthermore, claim 11 is drawn to a single IgA antibody of a desired binding specificity. The library does not even factor into this claim.

Conclusion

- 4. Claim 12 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 5. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing

Art Unit: 1644

date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (571) 272-0852. The examiner can normally be reached on M-Th 6:30-4:00 and Alternate Fridays 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

F. Pierre VanderVegt, Ph.D. Patent Examiner May 22, 2007

DAVID A. SAUNDERS PRIMARY EXAMINER